In the TH3RESA trial, T-DM1 significantly improved OS compared to previously treated with both trastuzumab and lapatinib (advanced setting) and a taxane (any setting for HER2+ advanced breast cancer) and with progression on two or more HER2-directed regimens in the advanced setting (39). Here, ERBB2 is linked to breast cancer.